Immunogenicity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients.
The immunogenicity of influenza vaccine is suboptimal in lung transplant recipients. Use of a booster dose and vaccine delivery by the intradermal rather than intramuscular route may improve response. We prospectively evaluated the immunogenicity and safety of a 2-dose boosting strategy of influenza vaccine. Sixty lung transplant recipients received a standard intramuscular injection of the 2006-2007 inactivated influenza vaccine, followed 4 weeks later by an intradermal booster of the same vaccine. Immunogenicity was assessed by measurement of geometric mean titer of antibodies after both the intramuscular injection and the intradermal booster. Vaccine response was defined as 4-fold or higher increase of antibody titers to at least one vaccine antigen. Thirty-eight out of 60 patients (63%) had a response after intramuscular vaccination. Geometric mean titers increased for all three vaccine antigens following the first dose (p < 0.001). However, no significant increases in titer were observed after the booster dose for all three antigens. Among nonresponders, 3/22 (13.6%) additional patients responded after the intradermal booster (p = 0.14). The use of basiliximab was associated with a positive response (p = 0.024). After a single standard dose of influenza vaccine, a booster dose given by intradermal injection did not significantly improve vaccine immunogenicity in lung transplant recipients.
Manuel
O
O
Transplant Infectious Diseases, University of Alberta, Edmonton, Alberta, Canada.
Humar
A
A
Chen
M H
MH
Chernenko
S
S
Singer
L G
LG
Cobos
I
I
Kumar
D
D
D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood; D005260:Female; D006801:Humans; D007117:Immunization, Secondary; D007252:Influenza Vaccines / Q000008:administration & dosage*; D007271:Injections, Intradermal; D007273:Injections, Intramuscular; D016040:Lung Transplantation / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D012449:Safety; D014611:Vaccination / Q000592:standards / Q000706:statistics & numerical data*; D015164:Vaccines, Inactivated / Q000008:administration & dosage*
D000914:Antibodies, Viral; D007252:Influenza Vaccines; D015164:Vaccines, Inactivated; C478242:vaxigrip